A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
Single-arm phase 2/3 trial (CLIMB THAL-111) of exagamglogene autotemcel (exa-cel, CTX001), CRISPR-Cas9-edited autologous CD34+ cells, in patients aged 12 to 35 with transfusion-dependent beta-thalassemia. At the interim analysis, 32 of 35 evaluable patients (91%) reached transfusion independence for at least 12 months.
| Status | Completed |
|---|---|
| Phase | Phase 2 3 |
| Primary Endpoint Result | Met |
| Enrollment | 59 |
| Start Date | 2018-09-14 |
| Primary Completion Date | 2025-11-13 |
Results Summary
No results are posted on ClinicalTrials.gov; the figures below come from the phase 3 interim analysis (NEJM 2024, data cutoff 16 January 2023, 52 treated patients, median follow-up 20.4 months). Transfusion independence for at least 12 months (hemoglobin 9 g/dL or higher without transfusion) occurred in 32 of 35 evaluable patients (91%; 95% CI 77 to 98; P<0.001 against a 50% response). Neutrophils and platelets engrafted in all 52 patients (median 29 and 44 days). During transfusion independence, mean total hemoglobin was 13.1 g/dL and mean fetal hemoglobin 11.9 g/dL. Serious adverse events occurred in 17 of 52 patients (33%), most commonly veno-occlusive liver disease (5 patients), attributed to busulfan. No deaths or cancers occurred. A later report (April 2025 cutoff) described 55 of 56 patients transfusion independent for at least 12 months.
Design Implications
Editing the erythroid-specific BCL11A enhancer reactivates fetal hemoglobin to levels that give transfusion independence in about 9 of 10 patients with transfusion-dependent beta-thalassemia, including beta0/beta0 genotypes that have no adult hemoglobin, so fetal hemoglobin induction does not depend on the underlying mutation. Benefit tracked stable editing of about 78% of bone marrow CD34+ alleles, which supports allelic editing as a practical manufacturing and release marker. The main toxicity came from the delivery procedure, not the edit: myeloablative busulfan caused veno-occlusive liver disease and grade 3 or 4 events in 88% of patients, and patients needed months to engraft. Gentler or non-genotoxic conditioning, or in vivo editing of stem cells, is the clearest route to wider access. Three patients with beta0/beta0-like genotypes and intact spleens reached transfusion independence late or not at all despite similar editing, so fetal hemoglobin kinetics, not editing level, may limit response.
Rationale
Exa-cel is autologous CD34+ hematopoietic stem and progenitor cells edited ex vivo with CRISPR-Cas9 and a single guide RNA at the erythroid-specific enhancer of BCL11A. BCL11A represses gamma-globin, so disrupting its enhancer in the erythroid lineage reactivates fetal hemoglobin (HbF). In beta-thalassemia, HbF can replace the missing adult beta-globin and balance the globin chains, as in patients who co-inherit hereditary persistence of fetal hemoglobin. Raising HbF and total hemoglobin was expected to remove the need for red-cell transfusions.
Limitations
Single-arm, open-label trial with no control group. The efficacy analysis covers only the 35 of 52 treated patients with at least 16 months of follow-up at a prespecified interim cutoff (median follow-up 20.4 months); the final analysis is not posted or published. Registered as phase 2/3 though titled phase 1/2/3. Sponsor-funded, ages 12 to 35 only, and the treatment required myeloablative busulfan.
Registry record
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.
| Primary Outcomes | Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12), Proportion of participants with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] ≥500/µL on three different days), Time to neutrophil and platelet engraftment, Frequency and severity of collected adverse events (AEs), Incidence of transplant-related mortality (TRM), All-cause mortality |
|---|---|
| Keywords | CRISPR-Cas9, Beta-Thalassemia, Hemoglobinopathies |
| Registry Last Updated | 2025-12-17 |
| Minimum Age | 12 Years |
| Modalities | gene_editing, cell_therapy |
| Maximum Age | 35 Years |
| Intervention Names | CTX001, Exagamglogene autotemcel, Exa-cel |
| Allocation | Not Applicable |
| Masking | None |
| Primary Purpose | Treatment |
| Has Results | No |
| Enrollment Type | Actual |
| Countries | United States, Canada, Germany, Italy, United Kingdom |
| Intervention Types | biological |
| Study Type | Interventional |
| Intervention Model | Single Group |
| Healthy Volunteers | No |
| Condition Terms | Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies, beta-Thalassemia |
| Completion Date | 2025-11-13 |
| Lead Sponsor Class | Industry |
| Eligibility Sex | All |
Official Title
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia
Eligibility Criteria
Key Inclusion Criteria:
-
Diagnosis of transfusion-dependent β-thalassemia (TDT) as defined by
- Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning
- History of at least 100 mL/kg/year or ≥10 units/year of packed RBC transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening
-
Eligible for autologous stem cell transplant as per investigator's judgment
Key Exclusion Criteria:
- A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is available per investigator's judgement
- Prior allo-HSCT
- Participants with associated α-thalassemia and >1 alpha deletion or alpha multiplications
- Participants with sickle cell beta thalassemia variant
- Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator
- White blood cell (WBC) count <3 × 10^9/L or platelet count <50 × 10^9/L not related to hypersplenism
Other protocol defined Inclusion/Exclusion criteria may apply.
Identifiers & revision
clinicaltrials NCT03655678
